Skip to main content

FARALLON CAPITAL MANAGEMENT LLC

Registered adviser
Location
SAN FRANCISCO, CA
Portfolio Value
Large $22,584,253,669
Diversification
Diversified
Filing Date
Global Rank
#326 / 8,710 ▼ 5
Top Industry
Biotechnology 42.2%
3Y Alpha vs SPY
-0.1%
Period ended 50 days ago
Filed Nov 16, 2026 · 3d
27 quarters · since Mar 2020

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type
Registered adviser
Form ADV roster, Nov 1, 2026
Form ADV adviser
CRD 107322
Roster of Nov 1, 2026
Regulatory AUM
$52,076,899,000
Main clients
Pooled investment vehicles (100% of AUM)
Private funds
50 funds · Hedge funds
Focus by fund count, roster of Nov 1, 2026
$64,458,583,000 gross assets
LEI
87DR6WT2MK1KMGUC7161
Private funds on Schedule D 7.B.(1)
As filed Oct 30, 2024; SEC's bulk Form ADV archive ends with 2024 filings.
$53,519,462,000 gross assets in 54 funds Hedge funds $53,519,462,000 (54)
Form ADV history
Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.
Rosters Regulatory AUM Main clients
Oct 2026 to Nov 2026 $52,076,899,000 Pooled investment vehicles (100%)
Apr 2026 to Sep 2026 $52,076,899,000 Pooled investment vehicles (100%)
Apr 2025 to Mar 2026 $48,267,892,000 Pooled investment vehicles (100%)
Jul 2024 to Mar 2025 $42,649,319,000 Pooled investment vehicles (100%)
Apr 2024 to Jun 2024 $42,649,319,000 Pooled investment vehicles (100%)
May 2023 to Mar 2024 $41,248,942,000 Pooled investment vehicles (100%)
5 earlier changes not shown.

Schedule 13D/13G stakes

Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.

Company Schedule Filed Shares % of class Status
EXEL Exelixis, Inc. 13G 10d 14,694,910 6% Current
AVTX Avalo Therapeutics, Inc. 13G 6d 3,974,000 7.4% Current
BBIO BridgeBio Pharma, Inc. 13G/A 7d 14,247,000 7.3% Current
AGIO Agios Pharmaceuticals, Inc. 13G/A 4mo 5,917,400 9.9% Current
ASMB Assembly Biosciences, Inc. 13G/A 4mo 1,604,590 8.1% Current
BEAM Beam Therapeutics Inc. 13G/A 3mo 10,282,210 9.99% Current
GRAL GRAIL, Inc. 13G/A 3mo 4,161,584 9.6% Current
LQDA Liquidia Corp 13G/A 4mo 8,365,038 9.4% Current
NERV Minerva Neurosciences, Inc. 13G/A 3mo 4,730,000 9.7% Current
PTGX Protagonist Therapeutics, Inc 13G/A 3mo 6,433,119 9.99% Current
RVMD Revolution Medicines, Inc. 13G/A 3mo 13,564,149 6.4% Current
SVRA Savara Inc 13G/A 3mo 15,000,000 6.8% Current

A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 10 exited, below-5% or retired stakes

Portfolio style

Measured from the filed 13F common-share book for Sep 30, 2026, never from the firm's own description.

Style
Diversified active
Top 10 weight 57.4%, 19.6 effective positions, active share 89.5% against the Russell 1000 as of 2026-09-30; it meets none of the index-like, systematic-like or concentrated tests
Turnover
Medium turnover
73.2% over the last four quarters (30% to under 100%)
Horizon
Long horizon
Value-weighted holding period 14.0 quarters (12+), a floor since 15.6% of the book was already held when coverage starts

Closest benchmark: the Russell 1000 as of 2026-09-30, active share 89.5%; sector active share 60.9% against the combined 13F book's sector weights.

Over time 27 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+. Stocks and the top 10 weight count issuers: share classes of one company are one stock, and options are left out, so they can differ from the position count and top 10 concentration of GetInstitutionSummary and GetInstitutionPortfolio, which count each listed share class.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

109 common stock positions · as of Sep 30, 2026 · Δ vs Jun 30, 2026
Top Position
14.8%
+1.0 pts
Top 5
38.8%
+3.4 pts
Top 10
57.4%
+4.2 pts
HHI
511
Dec 2023 → Sep 2026 · range 241 – 511
Diversified+36

Portfolio Trend

27 quarters · across all stocks

Sector Breakdown

Common stock positions · as of Sep 30, 2026
Sector % Portfolio Value
Healthcare 64.8% $12,021,104,170
Communication Services 12.6% $2,346,923,419
Technology 7.0% $1,306,893,268
Financial Services 4.2% $775,587,425
Consumer Cyclical 3.3% $620,286,455
Industrials 2.9% $543,439,793
Basic Materials 2.6% $477,543,868
Consumer Defensive 2.4% $451,545,010
Energy 0.0% $6,637,209
Real Estate 0.0% $5,057,240
Utilities 0.0% $4,905,900

Last Quarter's Activity

Export CSV
Sep 30, 2026 vs Jun 30, 2026

Added To

Positions the filer increased
24 positions
Ticker Δ Shares Shares Value Open
— +21,272,344 49,372,344 $1,528,074,046

Trimmed

Positions the filer reduced
20 positions
Ticker Δ Shares Shares Value Open

New Positions

Positions the filer opened this quarter
25 positions
Ticker Shares Value Open

Sold Out

Positions the filer fully exited
20 positions
Ticker Shares Value Open
— 7,919,500 $1,623,814,280
— 8,989,098 $336,372,047
— 1,060,000 $140,693,800

Portfolio Positions

Export CSV View 13F filing
111 tracked positions · $22,584,253,669 total · filing declares 116 positions · $23,212,840,535 · as of Sep 30, 2026
Showing 1–50 of 111 positions by value · page 1 of 3
Ticker Company Shares Value (USD) % of Portfolio History
49,372,344 $1,528,074,046 6.77%

Showing the top 50 of 111 positions. Create a free account to see every position, past quarters, search, filters and CSV export.

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.